688336.SH
三生国健
SSE · Healthcare · Biotechnology · CN
CNY 43.45
−8.81%Year over year
Reported trailing growth
- Revenue
- +248.9%
- EBITDA
- —
- EBIT
- +363.4%
- EPS
- +314.6%
- Free cash flow
- —
- Operating cash flow
- +899.8%
Forward estimates
Based on analyst estimates
- Revenue
- -51.9%
- EBITDA
- -80.9%
- EPS
- -91.4%
Three-year CAGR
- Revenue
- +72.0%
- EBITDA
- +178.7%
- EBIT
- +348.2%
- Net income
- +288.9%
- EPS
- +288.7%
- Free cash flow
- +511.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026